These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15034838)

  • 21. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
    Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
    Bongiovanni M; Chiesa E; Di Biagio A; Meraviglia P; Capetti A; Tordato F; Cicconi P; Biasi P; Bini T; d'Arminio Monforte A
    J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
    Persaud D; Palumbo P; Ziemniak C; Chen J; Ray SC; Hughes M; Havens P; Purswani M; Gaur AH; Chadwick EG;
    J Infect Dis; 2007 May; 195(10):1402-10. PubMed ID: 17436219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
    Chu CM; Cheng VC; Hung IF; Wong MM; Chan KH; Chan KS; Kao RY; Poon LL; Wong CL; Guan Y; Peiris JS; Yuen KY;
    Thorax; 2004 Mar; 59(3):252-6. PubMed ID: 14985565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.
    Kikuchi Y; Genka I; Ishizaki A; Sunagawa K; Yasuoka A; Oka S
    Clin Infect Dis; 2002 Aug; 35(4):488-90. PubMed ID: 12145735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
    Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M;
    J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
    Di Giambenedetto S; Bacarelli A; Pinnetti C; Colafigli M; Prosperi M; Gatti G; Cauda R; De Luca A
    Scand J Infect Dis; 2007; 39(9):813-8. PubMed ID: 17701721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
    Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
    J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.
    Vogel M; Voigt E; Michaelis HC; Sudhop T; Wolff M; Türler A; Sauerbruch T; Rockstroh JK; Spengler U
    Liver Transpl; 2004 Jul; 10(7):939-44. PubMed ID: 15237382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
    Chan KS; Lai ST; Chu CM; Tsui E; Tam CY; Wong MM; Tse MW; Que TL; Peiris JS; Sung J; Wong VC; Yuen KY
    Hong Kong Med J; 2003 Dec; 9(6):399-406. PubMed ID: 14660806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antiretroviral drugs in severe acute respiratory syndrome].
    Yazdanpanah Y; Guéry B
    Presse Med; 2006 Jan; 35(1 Pt 2):105-7. PubMed ID: 16462674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coroner criticised over conduct of SARS inquest.
    Parry J
    BMJ; 2004 Nov; 329(7476):1204. PubMed ID: 15550417
    [No Abstract]   [Full Text] [Related]  

  • 39. [SARS and occupational risk].
    Signorini S; Vonesch N; Di Renzi S; Tomao P; Pera A; Palmi S
    G Ital Med Lav Ergon; 2003; 25 Suppl(3):254-5. PubMed ID: 14979174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS: pharmacotherapy.
    Tsang K; Zhong NS
    Respirology; 2003 Nov; 8 Suppl():S25-30. PubMed ID: 15018130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.